Everyday Health on MSN

Is intermittent fasting safe for people with ulcerative colitis?

This time-restricted eating pattern has shown promise in some preliminary research, but is it recommended for use in UC? Find ...
The National Law Review

Ulcerative Colitis Treatment Market

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...
clinicaladvisor.com

Beyond Biologics: First-Line Oral Therapy for Severely Active Ulcerative Colitis

Oral small-molecule therapies are redefining first-line treatment in moderate to severe ulcerative colitis (UC) by offering noninfusion alternatives with rapid onset and high efficacy. Etrasimod, a ...
clinicaladvisor.com

Have Biologics Been Effective in Treating Ulcerative Colitis?

Credit: Getty Images What have we learned in recent years about the safety and efficacy of different biologics for the treatment of ulcerative colitis? Ulcerative colitis (UC) is a condition with a ...
EatingWell on MSN

4 supplements to avoid if you have ulcerative colitis, according to experts

These common supplements may actually be doing more harm than good.
Seeking Alpha

FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis (2023-10-26) | Seeking Alpha

Omvoh achieved primary and key secondary endpoints, including sustained clinical remission in pivotal trials Omvoh delivered significant improvement in bowel urgency, reported by people with UC as one ...
WebMD

Ulcerative Colitis vs. Proctitis: Similarities and Differences

What Is Proctitis and How Does It Compare to UC? Proctitis is inflammation of the rectum, the last part of the large intestine that connects the colon to the anus. Ulcerative colitis (UC) is a type of ...
Nasdaq

FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis

INDIANAPOLIS, Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh™ (mirikizumab-mrkz) infusion (300 ...